---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-076037"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2024-06-28T23:59:59+00:00"
generated_at: "2026-06-01T00:45:00.646488+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MindMed enters $150M ATM equity program with Leerink Partners, terminates prior ATM

## Summary
- New at-the-market sales agreement with Leerink Partners LLC authorizes sale of up to $150M in common shares.
- Agent commission capped at 3.0% of gross proceeds; company has no obligation to sell shares.
- Prior Controlled Equity Offering agreement with Cantor Fitzgerald and Oppenheimer terminated on May 28, 2024.
- Company may suspend or terminate the new ATM facility at any time.

## SEC filing metadata
- accession: 0001104659-24-076037
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2024-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000110465924076037/0001104659-24-076037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000110465924076037/tm2416299d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-076037
- JSON: https://secwatch.observer/filing/0001104659-24-076037.json
- Plain text: https://secwatch.observer/filing/0001104659-24-076037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.